247 related articles for article (PubMed ID: 10232595)
1. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
2. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
3. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
4. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors.
Takahashi T; Min Z; Uchida I; Arita M; Watanabe Y; Koi M; Hemmi H
Cancer Lett; 2005 Mar; 220(1):85-93. PubMed ID: 15737691
[TBL] [Abstract][Full Text] [Related]
6. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
7. Signalling cell cycle arrest and cell death through the MMR System.
O'Brien V; Brown R
Carcinogenesis; 2006 Apr; 27(4):682-92. PubMed ID: 16332722
[TBL] [Abstract][Full Text] [Related]
8. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
9. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
10. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea.
Aquilina G; Ceccotti S; Martinelli S; Soddu S; Crescenzi M; Branch P; Karran P; Bignami M
Clin Cancer Res; 2000 Feb; 6(2):671-80. PubMed ID: 10690553
[TBL] [Abstract][Full Text] [Related]
12. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.
Papouli E; Cejka P; Jiricny J
Cancer Res; 2004 May; 64(10):3391-4. PubMed ID: 15150090
[TBL] [Abstract][Full Text] [Related]
13. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.
Yan T; Berry SE; Desai AB; Kinsella TJ
Clin Cancer Res; 2003 Jun; 9(6):2327-34. PubMed ID: 12796402
[TBL] [Abstract][Full Text] [Related]
14. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of geno- and cytotoxicity of methylnitrosourea on MMR-proficient and MMR-deficient human tumor cell lines].
Tronov VA; Kramarenko II; Smirnova TD; Terekhov SM
Tsitologiia; 2006; 48(1):19-27. PubMed ID: 16568831
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
Branch P; Masson M; Aquilina G; Bignami M; Karran P
Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA mismatch repair for radiosensitization.
Berry SE; Kinsella TJ
Semin Radiat Oncol; 2001 Oct; 11(4):300-15. PubMed ID: 11677655
[TBL] [Abstract][Full Text] [Related]
18. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells.
Claij N; te Riele H
Oncogene; 2004 Jan; 23(1):260-6. PubMed ID: 14712231
[TBL] [Abstract][Full Text] [Related]
19. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
20. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
